Cargando…

Risk Stratified Follow-Up for Endometrial Cancer: The Clinicians’ Perspective

Risk-stratified follow-up for endometrial cancer (EC) is being introduced in many cancer centres; however, there appears to be diversity in the structure and availability of schemes across the UK. This study aimed to investigate clinicians’ and clinical specialist nurses’ (CNS) experiences of follow...

Descripción completa

Detalles Bibliográficos
Autores principales: Amirthanayagam, Anumithra, Boulter, Louise, Millet, Nessa, McDermott, Hilary J., Morrison, Jo, Taylor, Alexandra, Miles, Tracie, Coton, Lorna, Moss, Esther L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955652/
https://www.ncbi.nlm.nih.gov/pubmed/36826134
http://dx.doi.org/10.3390/curroncol30020173
_version_ 1784894399479545856
author Amirthanayagam, Anumithra
Boulter, Louise
Millet, Nessa
McDermott, Hilary J.
Morrison, Jo
Taylor, Alexandra
Miles, Tracie
Coton, Lorna
Moss, Esther L.
author_facet Amirthanayagam, Anumithra
Boulter, Louise
Millet, Nessa
McDermott, Hilary J.
Morrison, Jo
Taylor, Alexandra
Miles, Tracie
Coton, Lorna
Moss, Esther L.
author_sort Amirthanayagam, Anumithra
collection PubMed
description Risk-stratified follow-up for endometrial cancer (EC) is being introduced in many cancer centres; however, there appears to be diversity in the structure and availability of schemes across the UK. This study aimed to investigate clinicians’ and clinical specialist nurses’ (CNS) experiences of follow-up schemes for EC, including patient-initiated follow-up (PIFU), telephone follow-up (TFU) and clinician-led hospital follow-up (HFU). A mixed-methods study was conducted, consisting of an online questionnaire to CNSs, an audience survey of participants attending a national “Personalising Endometrial Cancer Follow-up” educational meeting, and qualitative semi-structured telephone interviews with clinicians involved in the follow-up of EC. Thematic analysis identified three main themes to describe clinicians’ views: appropriate patient selection; changing from HFU to PIFU schemes; and the future of EC follow-up schemes. Many participants reported that the COVID-19 pandemic impacted EC follow-up by accelerating the transition to PIFU/TFU. Overall, there was increasing support for non-HFU schemes for patients who have completed primary treatment of EC; however, barriers were identified for non-English-speaking patients and those who had communication challenges. Given the good long-term outcome associated with EC, greater focus is needed to develop resources to support patients post-treatment and individualise follow-up according to patients’ personal needs and preferences.
format Online
Article
Text
id pubmed-9955652
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99556522023-02-25 Risk Stratified Follow-Up for Endometrial Cancer: The Clinicians’ Perspective Amirthanayagam, Anumithra Boulter, Louise Millet, Nessa McDermott, Hilary J. Morrison, Jo Taylor, Alexandra Miles, Tracie Coton, Lorna Moss, Esther L. Curr Oncol Article Risk-stratified follow-up for endometrial cancer (EC) is being introduced in many cancer centres; however, there appears to be diversity in the structure and availability of schemes across the UK. This study aimed to investigate clinicians’ and clinical specialist nurses’ (CNS) experiences of follow-up schemes for EC, including patient-initiated follow-up (PIFU), telephone follow-up (TFU) and clinician-led hospital follow-up (HFU). A mixed-methods study was conducted, consisting of an online questionnaire to CNSs, an audience survey of participants attending a national “Personalising Endometrial Cancer Follow-up” educational meeting, and qualitative semi-structured telephone interviews with clinicians involved in the follow-up of EC. Thematic analysis identified three main themes to describe clinicians’ views: appropriate patient selection; changing from HFU to PIFU schemes; and the future of EC follow-up schemes. Many participants reported that the COVID-19 pandemic impacted EC follow-up by accelerating the transition to PIFU/TFU. Overall, there was increasing support for non-HFU schemes for patients who have completed primary treatment of EC; however, barriers were identified for non-English-speaking patients and those who had communication challenges. Given the good long-term outcome associated with EC, greater focus is needed to develop resources to support patients post-treatment and individualise follow-up according to patients’ personal needs and preferences. MDPI 2023-02-13 /pmc/articles/PMC9955652/ /pubmed/36826134 http://dx.doi.org/10.3390/curroncol30020173 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Amirthanayagam, Anumithra
Boulter, Louise
Millet, Nessa
McDermott, Hilary J.
Morrison, Jo
Taylor, Alexandra
Miles, Tracie
Coton, Lorna
Moss, Esther L.
Risk Stratified Follow-Up for Endometrial Cancer: The Clinicians’ Perspective
title Risk Stratified Follow-Up for Endometrial Cancer: The Clinicians’ Perspective
title_full Risk Stratified Follow-Up for Endometrial Cancer: The Clinicians’ Perspective
title_fullStr Risk Stratified Follow-Up for Endometrial Cancer: The Clinicians’ Perspective
title_full_unstemmed Risk Stratified Follow-Up for Endometrial Cancer: The Clinicians’ Perspective
title_short Risk Stratified Follow-Up for Endometrial Cancer: The Clinicians’ Perspective
title_sort risk stratified follow-up for endometrial cancer: the clinicians’ perspective
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955652/
https://www.ncbi.nlm.nih.gov/pubmed/36826134
http://dx.doi.org/10.3390/curroncol30020173
work_keys_str_mv AT amirthanayagamanumithra riskstratifiedfollowupforendometrialcancerthecliniciansperspective
AT boulterlouise riskstratifiedfollowupforendometrialcancerthecliniciansperspective
AT milletnessa riskstratifiedfollowupforendometrialcancerthecliniciansperspective
AT mcdermotthilaryj riskstratifiedfollowupforendometrialcancerthecliniciansperspective
AT morrisonjo riskstratifiedfollowupforendometrialcancerthecliniciansperspective
AT tayloralexandra riskstratifiedfollowupforendometrialcancerthecliniciansperspective
AT milestracie riskstratifiedfollowupforendometrialcancerthecliniciansperspective
AT cotonlorna riskstratifiedfollowupforendometrialcancerthecliniciansperspective
AT mossestherl riskstratifiedfollowupforendometrialcancerthecliniciansperspective